<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18243" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Beta-Lactam Antibiotics</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pandey</surname>
            <given-names>Neelanjana</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cascella</surname>
            <given-names>Marco</given-names>
          </name>
          <aff>Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Via Mariano Semmola 80100, Napoli. Italy</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Neelanjana Pandey declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Cascella declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18243.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Beta-lactam antibiotics are used in the management and treatment of bacterial infections. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of an interprofessional healthcare team in the treatment of patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of beta-lactam antibiotics.</p></list-item><list-item><p>Describe the possible adverse effects of beta-lactam antibiotics.</p></list-item><list-item><p>Outline the appropriate monitoring of patients taking beta-lactam antibiotics.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance beta-lactam antibiotics and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18243&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18243">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18243.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Beta-lactam antibiotics are one of the most commonly prescribed drug classes with numerous clinical indications. Their advent starting from the 30s of the twentieth century drastically changed the fight against bacterial infectious diseases. Nowadays, it has been calculated that the annual expenditure for these antibiotics amounts to approximately $15 billion USD, and it makes up 65% of the total antibiotics market.<xref ref-type="bibr" rid="article-18243.r1">[1]</xref>&#x000a0;Their use, however, clashes with the worrying phenomenon of antimicrobial resistance remains, which represents a global health issue.</p>
        <p>From a&#x000a0;biochemical point of view, these drugs have a common feature, which is the 3-carbon and 1-nitrogen ring (beta-lactam ring) that is highly reactive. This class includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Penicillins.&#x000a0;These antibiotics (most of which end in the suffix -<italic toggle="yes">cillin</italic>) contain a nucleus of 6-animopenicillanic acid (lactam plus thiazolidine) ring and other ringside chains. The group includes natural penicillins, beta-lactamase-resistant&#x000a0;agents, aminopenicillins, carboxypenicillins, and ureidopenicillins.</p>
          </list-item>
          <list-item>
            <p>Cephalosporins. They contain a 7-aminocephalosporanic acid nucleus and side-chain containing 3,6-dihydro-2 H-1,3- thiazane rings. Cephalosporins are traditionally&#x000a0;divided into five classes&#x000a0;or generations, although acceptance of this terminology is not universal.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Carbapenems. Their defining structure is a carbapenem coupled to a beta-lactam ring that confers protection against most&#x000a0;beta-lactamases, although resistance to these compounds is a significant issue and occurs mainly among gram-negative pathogens (e.g.,&#x000a0;<italic toggle="yes">Klebsiella pneumoniae</italic>,&#x000a0;<italic toggle="yes">Pseudomonas aeruginosa</italic>, and&#x000a0;<italic toggle="yes">Acinetobacter&#x000a0;baumannii),&#x000a0;</italic>which produce different classes of beta-lactamases termed as carbapenemase.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Monobactams. The beta-lactam ring&#x000a0;stands alone and not fused to another ring.</p>
          </list-item>
          <list-item>
            <p>Beta-lactamase inhibitors. They work primarily by inactivating serine beta-lactamases, which are enzymes that hydrolyze and inactivate the beta-lactam ring (especially in gram-negative bacteria). These agents include the first-generation beta-lactamase inhibitors (clavulanic acid, sulbactam, and tazobactam) and the newer&#x000a0;avibactam and vaborbactam that are active against carbapenemase such as&#x000a0;<italic toggle="yes">Klebsiella pneumoniae</italic>&#x000a0;carbapenemase (KPC).</p>
          </list-item>
        </list>
        <p>
<bold>Mechanism of Resistance</bold>
</p>
        <p>Resistance to beta-lactams is an alarming and growing phenomenon and, in turn, a public health challenge. It concerns, above all,&#x000a0;<italic toggle="yes">Streptococcus pneumoniae</italic> and individual gram-negative bacilli such as <italic toggle="yes">Pseudomonas aeruginosa</italic>. With emerging resistance for antibiotics, it makes sense to look into mechanisms of resistance as it can help decide which drugs to prescribe in different scenarios and ways to overcome the same. Although bacterial resistance to beta-lactams mostly expresses through the production of beta-lactamases, other mechanisms are involved. Following are the mechanisms of resistance<xref ref-type="bibr" rid="article-18243.r2">[2]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Inactivation by&#x000a0;the&#x000a0;production of beta-lactamases&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Decreased penetration to the target site (e.g., the resistance of <italic toggle="yes">Pseudomonas aeruginosa</italic>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Alteration of target site PBPs (e.g., penicillin resistance in pneumococci)</p>
          </list-item>
          <list-item>
            <p>Efflux from the periplasmic space through specific pumping mechanisms</p>
          </list-item>
        </list>
        <p>
<bold>Indications For Beta-Lactam Antibiotics</bold>
<bold/>
</p>
        <p>The indications for using the beta-lactam antibiotics are many and vary according to the subclass considered<xref ref-type="bibr" rid="article-18243.r3">[3]</xref></p>
        <p>
<bold>Penicillins</bold>
</p>
        <p>Natural penicillins [penicillin G (IV), penicillin V (PO)] are used to treat&#x000a0;selected gram-positive and gram-negative infections:</p>
        <list list-type="bullet">
          <list-item>
            <p>Penicillin susceptible <italic toggle="yes">Streptococcus pneumonia</italic> and meningitis</p>
          </list-item>
          <list-item>
            <p>Streptococcal pharyngitis</p>
          </list-item>
          <list-item>
            <p>Endocarditis</p>
          </list-item>
          <list-item>
            <p>Skin and soft tissue infections</p>
          </list-item>
          <list-item>
            <p>Neisseria meningitides infections</p>
          </list-item>
          <list-item>
            <p>Syphilis</p>
          </list-item>
        </list>
        <p>
<bold>Beta-lactamase-resistant Agents</bold>
</p>
        <p>These agents [oxacillin (IV), nafcillin (IV), dicloxacillin (PO)] are active against gram-positive organisms. Despite the occurrence of widespread resistance among staphylococci, they remain antibiotics of choice in managing methicillin-susceptible staphylococci (MSSA):</p>
        <list list-type="bullet">
          <list-item>
            <p>Skin and soft tissue infections (MSSA)</p>
          </list-item>
          <list-item>
            <p>Serious infections due to MSSA</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Aminopenicillins</italic>
</p>
        <p>These antibiotics have activity against gram-positive and gram-negative&#x000a0;bacteria&#x000a0;(e.g., many <italic toggle="yes">Enterobacteriaceae</italic>) anaerobic organisms. They are commonly&#x000a0;used together with beta-lactamase inhibitors.</p>
        <p>Amoxicillin (PO), ampicillin (PO/IV):</p>
        <list list-type="bullet">
          <list-item>
            <p>Upper respiratory tract infections (sinusitis, pharyngitis, otitis media)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Enterococcus faecalis</italic> infections</p>
          </list-item>
          <list-item>
            <p>Listeria infections</p>
          </list-item>
          <list-item>
            <p>Aminopenicillins/beta-lactamase inhibitors: amoxicillin/clavulanate (PO), ampicillin-sulbactam (IV)</p>
          </list-item>
          <list-item>
            <p>Upper respiratory tract infections (sinusitis, otitis media)</p>
          </list-item>
          <list-item>
            <p>Intra-abdominal infections</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Ureidopenicillins</italic>
</p>
        <p>Piperacillin (ureidopenicillin) has activity against&#x000a0;aminopenicillin-resistant gram-negative bacilli (<italic toggle="yes">Pseudomonas aeruginosa</italic>). They are commonly combined with beta-lactamase inhibitors.</p>
        <p>
<bold>Cephalosporins</bold>
</p>
        <p>
<italic toggle="yes">First-generation cephalosporins</italic>
</p>
        <p>Cefazolin(IV), cephalexin (PO), cefadroxil (PO)</p>
        <list list-type="bullet">
          <list-item>
            <p>Skin and soft tissue infections serious infections due to MSSA&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Perioperative surgical prophylaxis</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Second-generation cephalosporins</italic>
</p>
        <p>Cefuroxime (IV/PO), cefoxitin (IV), cefotetan (IV), cefaclor (PO) cefprozil (PO)</p>
        <list list-type="bullet">
          <list-item>
            <p>Upper respiratory tract infections (sinusitis, otitis media)</p>
          </list-item>
          <list-item>
            <p>Cefoxitin, cefotetan-gynecologic infections,</p>
          </list-item>
          <list-item>
            <p>perioperative surgical prophylaxis</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Third-generation cephalosporins</italic>
</p>
        <p>Cefotaxime (IV), ceftriaxone (IV), cefpodoxime (PO), cefixime (PO), cefdinir (PO), cefditoren (PO), ceftibuten (PO)</p>
        <list list-type="bullet">
          <list-item>
            <p>Community-acquired pneumonia, meningitis</p>
          </list-item>
          <list-item>
            <p>Urinary tract infections</p>
          </list-item>
          <list-item>
            <p>Streptococcal endocarditis</p>
          </list-item>
          <list-item>
            <p>Gonorrhea</p>
          </list-item>
          <list-item>
            <p>Severe Lyme disease.</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Anti-pseudomonal Cephalosporins</italic>
</p>
        <p>Ceftazidime (IV), ceftazidime/avibactam (IV), cefepime (IV) [Fourth-generation],&#x000a0;ceftolozone/tazobactam (IV) [also been described as "fifth-generation"]</p>
        <list list-type="bullet">
          <list-item>
            <p>Nosocomial infections-pneumonia</p>
          </list-item>
          <list-item>
            <p>Meningitis</p>
          </list-item>
          <list-item>
            <p>Complicated Intra-abdominal Infections (cIAI) [ceftazolone plus beta-lactamase&#x000a0;inhibitor]</p>
          </list-item>
          <list-item>
            <p>Complicated Urinary Tract Infections (cUTI)&#x000a0;[ceftazolone plus beta-lactamase&#x000a0;inhibitor]</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Anti-Methicillin-resistant Staphylococcus aureus (MRSA) cephalosporins</italic>
</p>
        <p>Ceftaroline (IV), ceftobiprole (IV) [Also been described as "fifth-generation"]&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Community-acquired pneumonia</p>
          </list-item>
          <list-item>
            <p>Hospital-acquired pneumonia (excluding ventilator-acquired pneumonia)</p>
          </list-item>
          <list-item>
            <p>Skin and soft tissue infection</p>
          </list-item>
        </list>
        <p>
<bold>Carbapenems</bold>
</p>
        <p>Imipenem/cilastatin (IV), meropenem (IV), doripenem (IV)</p>
        <list list-type="bullet">
          <list-item>
            <p>Nosocomial infections-pneumonia, intra-abdominal infections, urinary tract infections</p>
          </list-item>
          <list-item>
            <p>Meningitis (especially meropenem) &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <p>Ertapenem (IV)</p>
        <list list-type="bullet">
          <list-item>
            <p>Community-acquired infections</p>
          </list-item>
          <list-item>
            <p>Nosocomial infections.</p>
          </list-item>
        </list>
        <p>
<bold>Monobactams</bold>
</p>
        <p>Aztreonam (IV). It is&#x000a0;effective only against aerobic gram-negative organisms but shows no activity against gram-positive&#x000a0;bacteria or anaerobes.</p>
        <list list-type="bullet">
          <list-item>
            <p>Nosocomial infections, e.g., pneumonia</p>
          </list-item>
          <list-item>
            <p>Urinary tract infections &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <p>Because the emergence of antimicrobial resistance has become a&#x000a0;progressively&#x000a0;great concern, new beta-lactam and beta-lactamase inhibitor combinations (ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilastatin/relebactam, aztreonam/avibactam), siderophore-conjugated cephalosporins (cefiderocol), and siderophore-conjugated monobactams have been developed and represent options for the management of complicated infections,&#x000a0;especially in the intensive care unit.<xref ref-type="bibr" rid="article-18243.r4">[4]</xref><xref ref-type="bibr" rid="article-18243.r5">[5]</xref></p>
      </sec>
      <sec id="article-18243.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Peptidoglycan or murein is a vital constituent of the bacterial cell wall that provides mechanical stability to it. It is an extremely conserved constituent of both the gram-positive and gram-negative envelopes. Nevertheless,&#x000a0;peptidoglycan is a thick structure in gram-positive bacteria (&#x02265;10 layers), while it is thin (one or two layers) in gram-negative ones. Concerning its structure, peptidoglycan is composed of glycan chains made of N-acetylglucosamine and N-acetylmuramic acid di&#x000ad;saccharide subunits; the N-acetylmuramic part is linked to highly conserved pentapeptide or tetrapeptide stems (l-alanine&#x02013;d-isoglutamine&#x02013;l-lysine&#x02013;d-alanine&#x02013;[d-alanine].</p>
        <p>The beta-lactam antibiotics inhibit the last step in peptidoglycan synthesis by acylating the transpeptidase involved in cross-linking peptides to form peptidoglycan.&#x000a0;The targets for the actions of beta-lactam antibiotics are known as penicillin-binding proteins (PBPs). This binding, in turn, interrupts the terminal transpeptidation process and induces loss of viability and lysis, also through autolytic processes&#x000a0;within the bacterial cell.<xref ref-type="bibr" rid="article-18243.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-18243.s4" sec-type="Administration">
        <title>Administration</title>
        <p>When administered orally, one must consider that&#x000a0;food can affect oral absorption. Moreover, the absorption of some molecules such as cefuroxime and cefpodoxime becomes decreased by H2 blockers or nonabsorbable antacids. The administration of these agents&#x000a0;can be through different routes.</p>
        <list list-type="bullet">
          <list-item>
            <p>Penicillin V is preferable for oral administration, given 30 min before the meal or 2 hours after.</p>
          </list-item>
          <list-item>
            <p>Penicillin G is available in 2 parenteral preparations: benzathine and procaine.</p>
          </list-item>
          <list-item>
            <p>Penicillin G benzathine dosing is once monthly as it has a longer half-life.</p>
          </list-item>
          <list-item>
            <p>Penicillin G procaine is given once daily due to a shorter half-life.</p>
          </list-item>
          <list-item>
            <p>Neither should be administered intravenously to avoid serious toxicity.</p>
          </list-item>
          <list-item>
            <p>Penicillinase-resistant penicillins (oxacillin, cloxacillin, and dicloxacillin) are available in oral and parenteral preparations.</p>
          </list-item>
          <list-item>
            <p>Aminopenicillins: ampicillin and amoxicillin are available in both oral and parenteral preparations, though amoxicillin is preferred orally.</p>
          </list-item>
          <list-item>
            <p>Antipseudomonal penicillins: piperacillin is only available for parenteral administration.</p>
          </list-item>
          <list-item>
            <p>Most cephalosporins are absorbed readily after oral administration; the administration of others can be intramuscularly or intravenously.&#x000a0;</p>
          </list-item>
        </list>
        <p>Because beta-lactam antibiotics demonstrate a time-dependent effect on bacterial eradication&#x000a0;(the duration that the pathogen is exposed to the antibiotic is crucial for bacterial eradication), their continuous infusions may have advantages over&#x000a0;standard intermittent bolus dosing. This therapeutic approach is particularly effective, especially when pathogens present higher minimum inhibitory concentrations (MIC).<xref ref-type="bibr" rid="article-18243.r7">[7]</xref>&#x000a0;Thus, the time free drug concentrations remain above the MIC (fT&#x0003e;MIC) becomes a better predictor of killing.</p>
      </sec>
      <sec id="article-18243.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Compared to other classes, beta-lactam&#x000a0;agents are&#x000a0;usually safe and well-tolerated.<xref ref-type="bibr" rid="article-18243.r8">[8]</xref>&#x000a0;The most frequent side effects are allergic reactions that vary from&#x000a0;0.7% to 10%. These reactions may occur with any dosage form of penicillin and are mostly maculopapular rashes, whereas reports of anaphylaxis appear in 0.004 to 0.015% of patients.<xref ref-type="bibr" rid="article-18243.r9">[9]</xref>&#x000a0;Apart from allergic reactions, beta-lactams can induce other side effects. In particular, these are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Penicillin G and piperacillin are also associated with impaired hemostasis due to defective platelet aggregation.</p>
          </list-item>
          <list-item>
            <p>An IV injection of benzathine penicillin G has correlations with cardiorespiratory arrest and death.</p>
          </list-item>
          <list-item>
            <p>Cephalosporins carry associations with rare instances of bone marrow depression, including granulocytopenia.</p>
          </list-item>
          <list-item>
            <p>Some cephalosporins are potentially nephrotoxic and correlate with renal tubular necrosis. Ceftriaxone can cause jaundice in neonates by displacing bilirubin from albumin.</p>
          </list-item>
          <list-item>
            <p>It can also lead to biliary pseudolithiasis due to its high affinity for biliary calcium.</p>
          </list-item>
          <list-item>
            <p>Cefepime correlates with encephalopathy and nonconvulsive status epilepticus at high doses or in patients with renal dysfunction.</p>
          </list-item>
          <list-item>
            <p>Imipenem is associated with seizures when given in high doses to patients with CNS lesions or&#x000a0;renal insufficiency.<xref ref-type="bibr" rid="article-18243.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18243.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Penicillins are contraindicated in patients with previous anaphylactic reactions or serious skin reactions, for example, Stevens-Johnson syndrome and toxic epidermal necrosis.<xref ref-type="bibr" rid="article-18243.r8">[8]</xref></p>
      </sec>
      <sec id="article-18243.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Most of the available penicillins have a short half-life, less than an hour mostly. Administration of the parenteral agents is every four hours, usually when treating serious systemic infections with normal renal function.&#x000a0;Piperacillin and ampicillin require dose adjustment when given in patients with renal insufficiency (GFR less than 10 ml/min).&#x000a0;Other agents like nafcillin, oxacillin, cloxacillin, and dicloxacillin have the hepato-biliary mode of excretion and therefore require no modification in renal impairment.</p>
        <p>All penicillins achieve therapeutic levels in pleural, pericardial, peritoneal, synovial fluids, and urine. Of note,&#x000a0;cerebrospinal fluid (CSF) penetration is poor in the absence of inflammation but achieves therapeutic levels in meningitis.<xref ref-type="bibr" rid="article-18243.r11">[11]</xref></p>
      </sec>
      <sec id="article-18243.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Penicillins are the most commonly used broad-spectrum antibiotics by many clinicians, including primary care providers, internists, infectious disease experts, and nurse practitioners. Within the subgroups of penicillins, there are differences between the antibiotics in pharmacokinetics, coverage, safety, and cost, which gives a fair amount of choice to make in selecting which drug to use.<xref ref-type="bibr" rid="article-18243.r12">[12]</xref></p>
        <p>Their use still requires the coordination of an interprofessional team. The clinicians above will be ordering/prescribing, but nursing will often administer (inpatient) or counsel on administration (outpatient).&#x000a0; Pharmacists need to involve themselves via medication reconciliation, looking for interactions, and reinforcing administration instructions. Nurses will often be the first line of contact in the event of adverse events and are also well-positioned to evaluate therapeutic effectiveness. Pharmacists shall verify dosing and duration of therapy and contact the prescriber on encountering any discrepancy. All healthcare team members need to be mindful of anaphylactic reactions to beta-lactam agents and the potential for crossover allergies and communicate these to the team when present.</p>
        <p>Although beta-lactams use is very common, their effective prescription requires an interprofessional team approach for optimal patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-18243.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18243&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18243">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18243/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18243">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18243.s10">
        <title>References</title>
        <ref id="article-18243.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thakuria</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lahon</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Beta Lactam Antibiotics as an Empirical Therapy in a Developing Country: An Update on Their Current Status and Recommendations to Counter the Resistance against Them.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>1207</fpage>
            <page-range>1207-14</page-range>
            <pub-id pub-id-type="pmid">23905143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ibrahim</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Shahrai</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Elamin</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Phenotypic Characterization and Antibiotic Resistance Patterns of Extended-Spectrum <italic>&#x003b2;</italic>-Lactamase- and AmpC <italic>&#x003b2;</italic>-Lactamase-Producing Gram-Negative Bacteria in a Referral Hospital, Saudi Arabia.</article-title>
            <source>Can J Infect Dis Med Microbiol</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>6054694</fpage>
            <pub-id pub-id-type="pmid">31346353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Probst-Kepper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Geginat</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria].</article-title>
            <source>Anasthesiol Intensivmed Notfallmed Schmerzther</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>53</volume>
            <issue>7-08</issue>
            <fpage>529</fpage>
            <page-range>529-542</page-range>
            <pub-id pub-id-type="pmid">30036899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Damiani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pezone</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Cascella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alfieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pace</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Fiore</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>New antimicrobial options for the management of complicated intra-abdominal infections.</article-title>
            <source>Eur J Clin Microbiol Infect Dis</source>
            <year>2019</year>
            <month>May</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>819</fpage>
            <page-range>819-827</page-range>
            <pub-id pub-id-type="pmid">30903538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cascella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pezone</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fiore</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>New antibiotics for the treatment of serious infections in intensive care unit patients.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1331</fpage>
            <page-range>1331-1334</page-range>
            <pub-id pub-id-type="pmid">30760041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eckburg</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Lister</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Walpole</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keutzer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Utley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tomayko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Farinola</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with &#x003b2;-Lactam Antibiotics in Healthy Subjects.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>63</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31262767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lodise</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Lomaestro</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Drusano</surname>
                <given-names>GL</given-names>
              </name>
              <collab>Society of Infectious Diseases Pharmacists</collab>
            </person-group>
            <article-title>Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.</article-title>
            <source>Pharmacotherapy</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>1320</fpage>
            <page-range>1320-32</page-range>
            <pub-id pub-id-type="pmid">16945055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiriac</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rerkpattanapipat</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bousquet</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Molinari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Demoly</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Optimal step doses for drug provocation tests to prove beta-lactam hypersensitivity.</article-title>
            <source>Allergy</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>552</fpage>
            <page-range>552-561</page-range>
            <pub-id pub-id-type="pmid">27569064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Shtessel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>144</volume>
            <issue>2</issue>
            <fpage>381</fpage>
            <page-range>381-392</page-range>
            <pub-id pub-id-type="pmid">31247266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Podlecka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jerzynska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Malewska-Kaczmarek</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stelmach</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>A Case of a Child With Several Anaphylactic Reactions to Drugs.</article-title>
            <source>Glob Pediatr Health</source>
            <year>2019</year>
            <volume>6</volume>
            <fpage>2333794X19855287</fpage>
            <pub-id pub-id-type="pmid">31259207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mortensen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doogue</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Preanalytical Stability of Piperacillin, Tazobactam, Meropenem, and Ceftazidime in Plasma and Whole Blood Using Liquid Chromatography-Tandem Mass Spectrometry.</article-title>
            <source>Ther Drug Monit</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>538</fpage>
            <page-range>538-543</page-range>
            <pub-id pub-id-type="pmid">31306394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18243.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Velkov</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Creek</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant <italic>Acinetobacter baumannii</italic>.</article-title>
            <source>Front Pharmacol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>754</fpage>
            <pub-id pub-id-type="pmid">31333468</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
